1DAL LAGO L, DHONDT V, AWADA A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors [ J ]. Oncologist, 2008, 13 (8) :845 - 858.
2GARNETT M J, MARAIS R. Guilty as charged: B-RAF is a human oncogene [ J ]. Cancer Cell,2004,6 (4) :313 - 319.
3WILHELM S M, CARTER C,TANG L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [ J ]. Can Res, 2004,64 ( 19 ) : 7099 - 7109.
4LIU L,CAO Y,CHEN C ,et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC /PRF/5 [ J ]. Can Res,2006,66(24) :11851 - 11858.
5CLARK J W, EDER J P, RYAN D, et al. Safety and pharmacokinetics of the dualaction Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors [ J ]. Clin Can Res, 2005,11 ( 15 ) : 5472 - 5480.
6AWADA A, HENDLISZ A, GIL T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours[J]. Brit J Can , 2005,92(10) : 1855 - 1861.
7MOORE M, HIRTE H W, SIU L, et al. Phase 1 study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors [J].Anna Onco 2005,16(10) :1688 - 1694.
8STRUMBERG D, RICHLY H, HILGER R A,et al. Phase Ⅰ clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors [ J ]. J Clin Onco , 2005, 23 (5) :965 -972.
9ABOU-ALFA G K, SCHWARTZ L, RICCI S, et al. Phase Ⅱ study of BAY 43-9006 in patients with advanced hepatocellular carcinoma [J].J Clin Onco, 2006, 24(26):4293- 4300.
10YAU T, CHAN P, NG K K, et al. Phase Ⅱ open-label study of singleagent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response[J]. Cancer,2009,115 ( 2 ) :428 - 436.
